Dexibuprofen

證據等級: L5

預測適應症: 10 個

Dexibuprofen: From Pain & Inflammation to Ankylosing Spondylitis

One-Sentence Summary

Dexibuprofen is the pharmacologically active S(+)-enantiomer of ibuprofen, a non-steroidal anti-inflammatory drug (NSAID) widely used for pain relief, fever reduction, and inflammatory conditions. The TxGNN model predicts it may be effective for Ankylosing Spondylitis—a chronic inflammatory arthritis of the spine—with 0 clinical trials but 3 published studies (including a systematic review of randomised controlled trials) currently supporting this direction. Among the 10 TxGNN-predicted indications, ankylosing spondylitis stands out as the only candidate with meaningful biological plausibility and real-world literature support.

Quick Overview

Item	Content
Original Indication	Pain, fever, and inflammatory conditions (general NSAID use)
Predicted New Indication	Ankylosing Spondylitis
TxGNN Prediction Score	99.70%
Evidence Level	L2 (Systematic Review of RCTs available)
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, Dexibuprofen is the S(+)-enantiomer of ibuprofen—the biologically active form that carries the full COX-inhibitory activity of the racemate. By selectively inhibiting cyclooxygenase enzymes (COX-1 and COX-2), it reduces prostaglandin E₂ (PGE₂) synthesis, thereby suppressing inflammation, pain, and fever. Because the inactive R(-)-enantiomer is eliminated, the same therapeutic effect is achievable at roughly half the total drug load compared to racemic ibuprofen.

Ankylosing spondylitis (AS) is a chronic HLA-B27–associated spondyloarthropathy characterised by axial inflammation, progressive spinal ankylosis, and elevated prostaglandin activity. The PGE₂/COX pathway is directly implicated in three key AS disease processes: (1) PGE₂ promotes IL-17 production and Th17 cell differentiation, amplifying the inflammatory cascade; (2) PGE₂ stimulates osteoclast activation and suppresses osteoprotegerin (OPG), driving the paradoxical bone loss and pathological new-bone formation that define AS; and (3) PGE₂ mediates the spinal pain and morning stiffness that are the hallmark symptoms of active disease.

NSAIDs are already the first-line pharmacological treatment for AS per the 2022 ASAS/EULAR guidelines. Dexibuprofen offers a theoretically cleaner pharmacokinetic profile—equivalent COX inhibition at a lower total dose, with improved gastrointestinal tolerability compared to racemic ibuprofen. Clinical data from the 1990s (Seractil® programme) included double-blind RCTs in patients with ankylosing spondylitis specifically, making this prediction biologically and clinically plausible rather than a computational artefact.

Clinical Trial Evidence

Currently no related clinical trials registered for Dexibuprofen in ankylosing spondylitis.

Note: NSAIDs as a drug class have extensive trial data in AS (diclofenac, naproxen, celecoxib). However, Dexibuprofen-specific AS trials have not been registered in ClinicalTrials.gov or ICTRP. Existing evidence derives from older European RCT programmes conducted before mandatory trial registration.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9013382	1996	Systematic Review of RCTs	Journal of Clinical Pharmacology	Re-evaluation of multiple double-blind RCTs of Dexibuprofen (Seractil®) across inflammatory and degenerative diseases including ankylosing spondylitis, rheumatoid arthritis, gonarthrosis, and lumbar syndrome; used Mann-Whitney statistics with confidence intervals for standardised cross-disease efficacy comparison
11771569	2001	Narrative Clinical Review	Clinical Rheumatology	Overview of Dexibuprofen clinical programme: 8 GCP-compliant trials (1,463 patients), 6 double-blind studies vs. placebo, racemic ibuprofen, and diclofenac; meta-analysis of 5 trials; data on dose-finding, pharmacokinetics, tolerability, and special indications including rheumatological conditions
21175420	2010	Technology/Formulation Review	Critical Reviews in Therapeutic Drug Carrier Systems	Reviews microencapsulation strategies for NSAIDs including Dexibuprofen in arthritis management (osteoarthritis, rheumatoid arthritis, septic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis), addressing challenges of joint-targeted drug delivery and tissue degeneration retardation

India Market Information

Dexibuprofen (DB09213) currently has no registered authorisations in India. No product licences, dosage form approvals, or market authorisations are on record.

This is a significant regulatory gap. To advance any repurposing programme, an entirely new regulatory submission (IND or NDA equivalent) would be required.

Safety Considerations

Please refer to the package insert for safety information.

Data Gap Notice: TFDA/CDSCO package insert warnings and contraindications were not retrieved in this Evidence Pack (Data Gap DG001 — Severity: Blocking). Drug-drug interaction data also returned no results from the DDI database query. Before any clinical or regulatory action, a full safety dossier must be assembled from the approved SmPC (Seractil® is approved in several European markets) and DrugBank records.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Ankylosing spondylitis is the only TxGNN-predicted indication for Dexibuprofen with credible biological grounding and published clinical data; NSAIDs are already the guideline-recommended first-line treatment for AS, and Dexibuprofen’s COX-inhibitory mechanism is directly relevant to the prostaglandin-driven inflammatory pathways that drive AS symptoms and progression. The 1996 systematic review of RCTs (PMID 9013382) specifically included AS patients, providing L2-level evidence. However, Dexibuprofen is not registered in India and lacks a formal safety package in this submission, creating blocking gaps before any development pathway can be opened.

To proceed, the following is needed:

Regulatory safety package (Blocking — DG001): Retrieve the approved European SmPC (Seractil®, Austria/Germany) and parse all warnings, contraindications, and special-population restrictions. This is required before Safety Stage 1 can be completed.
Mechanism of action documentation (High — DG002): Query DrugBank API for full MOA, pharmacokinetics, and target data for Dexibuprofen to support mechanistic rationale in any regulatory submission.
Dexibuprofen-specific RCT data extraction: The 1990s Seractil® clinical programme included AS-specific double-blind data; full trial reports should be obtained from the Mundipharma/STADA regulatory dossier or literature archives to determine effect size and safety profile vs. comparator NSAIDs.
India regulatory pathway assessment: Since the drug is not marketed in India, determine whether a new drug application, bridging study strategy, or partnership with an existing NSAID manufacturer (racemic ibuprofen holders) would be the most efficient path to market.
Comparative effectiveness positioning: Define the clinical value proposition vs. widely available NSAIDs (diclofenac, naproxen, celecoxib) in the Indian AS patient population — particularly the GI tolerability advantage at the lower enantiomeric dose.
Dismiss Ranks 1–7 and 10 as artefacts: Brachydactyly-syndactyly syndrome, colobomatous microphthalmia-rhizomelic dysplasia, acromesomelic dysplasia (Hunter-Thompson), brachyolmia-amelogenesis imperfecta, myosclerosis, brachyolmia, pseudoachondroplasia, and WHIM syndrome all represent topology proximity artefacts in the TxGNN knowledge graph (musculoskeletal/rare disease node clustering) with zero biological plausibility for COX inhibition and no supporting data; these should be formally closed as non-viable candidates.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.